Abstract
Background: Image-guided thermal ablations are commonly used in the treatment of thyroid nodules. Radiofrequency ablation (RFA) and laser ablation are the most commonly used. Here we aimed to obtain solid evidence of the long-term efficacy of RFA and laser ablation in benign non-functioning solid thyroid nodules (BNFSTN). Methods: PubMed, CENTRAL, Scopus, and Web of Science were searched until March 2019. Studies reporting the effectiveness of RFA or laser ablation in patients with BNFSTN in terms of volume reduction rate (VRR), compressive symptoms and cosmetic concerns were included. Complications were also assessed. Results: Out of 963 papers, 12 studies on RFA and 12 on laser ablation were included, assessing 1186 and 2009 BNFSTNs, respectively. Overall, VRR at 6, 12, 24, and 36 months was 60%, 66%, 62%, and 53%. VRR of RFA was 68%, 75%, and 87%, respectively. VRR of laser ablation was 48%, 52%, 45%, and 44%, respectively. Baseline volume of nodules undergone RFA was significantly smaller compared to laser ablation (20.1 ± 22.4 versus 24.6 ± 23.6 ml; p < 0.01). Nodules smaller than 30 ml obtained better outcomes than larger ones. A significant reduction in compressive symptoms and cosmetic concerns was found after RFA. Conclusions: This meta-analysis showed that both RFA and laser ablation are able to obtain a significant volume reduction in BNFSTNs. A significant volume reduction is already evident at 6 months after thermal ablation and results are stable over the time.
| Original language | English |
|---|---|
| Pages (from-to) | 172-182 |
| Number of pages | 11 |
| Journal | Endocrine |
| Volume | 34 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2020 |
Fingerprint
Keywords
- Laser ablation
- Meta-analysis
- Non-functioning thyroid nodules
- Radiofrequency ablation
- Volume reduction rate
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Efficacy of thermal ablation in benign non-functioning solid thyroid nodule : A systematic review and meta-analysis. / Trimboli, Pierpaolo; Castellana, Marco; Sconfienza, Luca Maria; Virili, Camilla; Pescatori, Lorenzo Carlo; Cesareo, Roberto; Giorgino, Francesco; Negro, Roberto; Giovanella, Luca; Mauri, Giovanni.
In: Endocrine, Vol. 34, No. 1, 01.2020, p. 172-182.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of thermal ablation in benign non-functioning solid thyroid nodule
T2 - A systematic review and meta-analysis
AU - Trimboli, Pierpaolo
AU - Castellana, Marco
AU - Sconfienza, Luca Maria
AU - Virili, Camilla
AU - Pescatori, Lorenzo Carlo
AU - Cesareo, Roberto
AU - Giorgino, Francesco
AU - Negro, Roberto
AU - Giovanella, Luca
AU - Mauri, Giovanni
PY - 2020/1
Y1 - 2020/1
N2 - Background: Image-guided thermal ablations are commonly used in the treatment of thyroid nodules. Radiofrequency ablation (RFA) and laser ablation are the most commonly used. Here we aimed to obtain solid evidence of the long-term efficacy of RFA and laser ablation in benign non-functioning solid thyroid nodules (BNFSTN). Methods: PubMed, CENTRAL, Scopus, and Web of Science were searched until March 2019. Studies reporting the effectiveness of RFA or laser ablation in patients with BNFSTN in terms of volume reduction rate (VRR), compressive symptoms and cosmetic concerns were included. Complications were also assessed. Results: Out of 963 papers, 12 studies on RFA and 12 on laser ablation were included, assessing 1186 and 2009 BNFSTNs, respectively. Overall, VRR at 6, 12, 24, and 36 months was 60%, 66%, 62%, and 53%. VRR of RFA was 68%, 75%, and 87%, respectively. VRR of laser ablation was 48%, 52%, 45%, and 44%, respectively. Baseline volume of nodules undergone RFA was significantly smaller compared to laser ablation (20.1 ± 22.4 versus 24.6 ± 23.6 ml; p < 0.01). Nodules smaller than 30 ml obtained better outcomes than larger ones. A significant reduction in compressive symptoms and cosmetic concerns was found after RFA. Conclusions: This meta-analysis showed that both RFA and laser ablation are able to obtain a significant volume reduction in BNFSTNs. A significant volume reduction is already evident at 6 months after thermal ablation and results are stable over the time.
AB - Background: Image-guided thermal ablations are commonly used in the treatment of thyroid nodules. Radiofrequency ablation (RFA) and laser ablation are the most commonly used. Here we aimed to obtain solid evidence of the long-term efficacy of RFA and laser ablation in benign non-functioning solid thyroid nodules (BNFSTN). Methods: PubMed, CENTRAL, Scopus, and Web of Science were searched until March 2019. Studies reporting the effectiveness of RFA or laser ablation in patients with BNFSTN in terms of volume reduction rate (VRR), compressive symptoms and cosmetic concerns were included. Complications were also assessed. Results: Out of 963 papers, 12 studies on RFA and 12 on laser ablation were included, assessing 1186 and 2009 BNFSTNs, respectively. Overall, VRR at 6, 12, 24, and 36 months was 60%, 66%, 62%, and 53%. VRR of RFA was 68%, 75%, and 87%, respectively. VRR of laser ablation was 48%, 52%, 45%, and 44%, respectively. Baseline volume of nodules undergone RFA was significantly smaller compared to laser ablation (20.1 ± 22.4 versus 24.6 ± 23.6 ml; p < 0.01). Nodules smaller than 30 ml obtained better outcomes than larger ones. A significant reduction in compressive symptoms and cosmetic concerns was found after RFA. Conclusions: This meta-analysis showed that both RFA and laser ablation are able to obtain a significant volume reduction in BNFSTNs. A significant volume reduction is already evident at 6 months after thermal ablation and results are stable over the time.
KW - Laser ablation
KW - Meta-analysis
KW - Non-functioning thyroid nodules
KW - Radiofrequency ablation
KW - Volume reduction rate
UR - http://www.scopus.com/inward/record.url?scp=85069532502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069532502&partnerID=8YFLogxK
U2 - 10.1007/s12020-019-02019-3
DO - 10.1007/s12020-019-02019-3
M3 - Article
AN - SCOPUS:85069532502
VL - 34
SP - 172
EP - 182
JO - Endocrine
JF - Endocrine
SN - 1355-008X
IS - 1
ER -